The Impact of Intrathecal Baclofen Therapy on Health-related Quality of Life for Children with Marked Hypertonia

Purpose: To investigate the effects of intrathecal baclofen therapy (ITB) on health-related quality of life for children with cerebral palsy and neurological conditions. Method: This study is part of a longitudinal, multicentre audit. The primary outcome measure, the Caregiver Priorities and Child H...

Full description

Saved in:
Bibliographic Details
Published inDevelopmental neurorehabilitation Vol. 23; no. 8; pp. 542 - 547
Main Authors Stewart, Kirsty, Copeland, Lisa, Lewis, Jennifer
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 16.11.2020
Subjects
Adolescent
Baclofen - administration & dosage
Baclofen - therapeutic use
cerebral palsy
Cerebral Palsy - complications
Cerebral Palsy - drug therapy
Cerebral Palsy - psychology
Child
Child, Preschool
Cohort Studies
Disabled Children
dystonia
Female
Humans
Injections, Spinal
Intrathecal baclofen
Longitudinal Studies
Male
Muscle Hypertonia - drug therapy
Muscle Hypertonia - etiology
Muscle Hypertonia - psychology
Muscle Relaxants, Central - administration & dosage
Muscle Relaxants, Central - therapeutic use
quality of life
Quality of Life - psychology
spasticity
Treatment Outcome
cerebral palsy
spasticity
Intrathecal baclofen
quality of life
dystonia
Online AccessGet full text

Cover

More Information
Summary:Purpose: To investigate the effects of intrathecal baclofen therapy (ITB) on health-related quality of life for children with cerebral palsy and neurological conditions. Method: This study is part of a longitudinal, multicentre audit. The primary outcome measure, the Caregiver Priorities and Child Health Index of Life with Disabilities, was completed at baseline, 6 and 12 months post ITB implant. Results: Forty subjects with cerebral palsy and other neurological conditions demonstrated significant improvement in aspects of health-related quality of life following ITB therapy, mean change 42.3 (SD 14.9) at baseline to 53.3 (SD 14.7) at 12 months (p< .001). Conclusion: Evidence to demonstrate the utility of ITB in pediatric populations beyond spasticity and dystonia reduction is limited. Our findings suggest that ITB improves aspects of quality of life, comfort, and ease of caregiving in children with cerebral palsy and other neurological conditions.
ISSN:1751-8423
1751-8431
DOI:10.1080/17518423.2020.1753841